{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:28:10Z","timestamp":1763202490415,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40272-021-00443-5","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:26:29Z","timestamp":1617420389000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeted Therapy for Pediatric Psoriasis"],"prefix":"10.1007","volume":"23","author":[{"given":"Miguel","family":"Nogueira","sequence":"first","affiliation":[]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,3]]},"reference":[{"key":"443_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol."},{"key":"443_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","volume":"33","author":"J Kim","year":"2015","unstructured":"Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33:13\u201323.","journal-title":"Dermatol Clin."},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","volume":"16","author":"R Sabat","year":"2007","unstructured":"Sabat R, Philipp S, H\u00f6flich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16:779\u201398.","journal-title":"Exp Dermatol."},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605\u201313.","journal-title":"J Immunol."},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475.","journal-title":"Int J Mol Sci."},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40257-017-0294-9","volume":"18","author":"M Relvas","year":"2017","unstructured":"Relvas M, Torres T. Pediatric psoriasis. Am J Clin Dermatol. 2017;18:797\u2013811.","journal-title":"Am J Clin Dermatol."},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs. 2020;22:199\u2013216.","journal-title":"Paediatr Drugs."},{"key":"443_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14:585\u201399.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/pde.13382","volume":"35","author":"LF Eichenfield","year":"2018","unstructured":"Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35:170\u201381.","journal-title":"Pediatr Dermatol."},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40272-020-00394-3","volume":"22","author":"QBD Nguyen","year":"2020","unstructured":"Nguyen QBD, Starling CT, Hebert AA. The use of TNF\u03b1 inhibitors in treating pediatric skin disorders. Paediatr Drugs. 2020;22:311\u20139.","journal-title":"Paediatr Drugs."},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2019.05.056","volume":"82","author":"P Lansang","year":"2020","unstructured":"Lansang P, Bergman JN, Fiorillo L, Joseph M, Lara-Corrales I, Marcoux D, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol. 2020;82:213\u201321.","journal-title":"J Am Acad Dermatol."},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241\u201351.","journal-title":"N Engl J Med."},{"issue":"280\u20137","key":"443_CR14","first-page":"e3","volume":"74","author":"AS Paller","year":"2016","unstructured":"Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(280\u20137):e3.","journal-title":"J Am Acad Dermatol."},{"key":"443_CR15","unstructured":"European Medicines Agency. HUMIRA\u00ae (adalimumab): EPAR product information. 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Accessed 7 Mar 2021."},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Tha\u00e7i D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390:40\u20139.","journal-title":"Lancet"},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/bjd.18029","volume":"181","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181:1177\u201389.","journal-title":"Br J Dermatol."},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","volume":"29","author":"V Di Lernia","year":"2018","unstructured":"Di Lernia V, Guarneri C, Stingeni L, Gisondi P, Bonamonte D, Calzavara Pinton PG, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018;29:217\u20139.","journal-title":"J Dermatolog Treat."},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"e13091","DOI":"10.1111\/dth.13091","volume":"32","author":"V Di Lernia","year":"2019","unstructured":"Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, et al. Adalimumab in severe plaque psoriasis of childhood: a multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther. 2019;32:e13091.","journal-title":"Dermatol Ther."},{"key":"443_CR20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D33XF9F397","volume":"11","author":"NN Farnsworth","year":"2005","unstructured":"Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11:11.","journal-title":"Dermatol Online J."},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.0736-8046.2004.21121.x","volume":"21","author":"MA Menter","year":"2004","unstructured":"Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87\u20138.","journal-title":"Pediatr Dermatol."},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/ijd.13752","volume":"56","author":"R Ramos Pinheiro","year":"2017","unstructured":"Ramos Pinheiro R, Diamantino F, Cabete J, Brasileiro A, Baptista J, Lopes MJP. Switching biologics in severe pediatric psoriasis: a retrospective analysis. Int J Dermatol. 2017;56:1461\u20134.","journal-title":"Int J Dermatol."},{"key":"443_CR23","first-page":"e652","volume":"8","author":"SK Saikaly","year":"2016","unstructured":"Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend. Cureus. 2016;8:e652.","journal-title":"Cureus."},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/jdv.13388","volume":"30","author":"V Tsang","year":"2016","unstructured":"Tsang V, Dvorakova V, Enright F, Murphy M, Gleeson C. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e117\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"443_CR25","first-page":"300060520912091","volume":"48","author":"J Lu","year":"2020","unstructured":"Lu J, Li Y, Yu N, Chen F, Ding Y, Yi X. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports. J Int Med Res. 2020;48:300060520912091.","journal-title":"J Int Med Res."},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40272-020-00383-6","volume":"22","author":"YW Huang","year":"2020","unstructured":"Huang YW, Tsai TF. Pharmacological management of pediatric pustular psoriasis. Paediatr Drugs. 2020;22:265\u201377.","journal-title":"Paediatr Drugs."},{"key":"443_CR27","unstructured":"U.S. Food and Drug Administration. STELARA\u00ae (ustekinumab): Highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s150lbl.pdf. Accessed 7 Mar 2021."},{"key":"443_CR28","unstructured":"European Medicines Agency. STELARA\u00ae (ustekinumab): EPAR product information. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf. Accessed at 7 Mar 2021."},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73:594\u2013603.","journal-title":"J Am Acad Dermatol."},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.19018","volume":"183","author":"S Philipp","year":"2020","unstructured":"Philipp S, Menter A, Nikkels AF, Barber K, Landells I, Eichenfield LF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664\u201372.","journal-title":"Br J Dermatol."},{"issue":"4","key":"443_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/jdv.17002","volume":"35","author":"C Bodemer","year":"2021","unstructured":"Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomised, controlled trial. J Eur Acad Dermatol Venereol. 2021;35(4):938\u201347. https:\/\/doi.org\/10.1111\/jdv.17002.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"443_CR32","unstructured":"European Medicines Agency. TALTZ\u00ae (ixekizumab): EPAR product information. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz#product-information-section. Accessed at 28 Dec 2020."},{"key":"443_CR33","unstructured":"U.S. Food and Drug Administration. TALTZ\u00ae (ixekizumab): Highlights of prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125521s020lbl.pdf. Accessed at 7 Mar 2021."},{"key":"443_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231\u201341.","journal-title":"Br J Dermatol."},{"key":"443_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14740338.2020.1730326","volume":"19","author":"H Iznardo","year":"2020","unstructured":"Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19:365\u201372.","journal-title":"Expert Opin Drug Saf."},{"key":"443_CR36","doi-asserted-by":"publisher","first-page":"212594","DOI":"10.7573\/dic.212594","volume":"8","author":"M Nogueira","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis \u2013 evidence to date. Drugs Context. 2019;8:212594.","journal-title":"Drugs Context."},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14740338.2020.1736034","volume":"19","author":"YW Huang","year":"2020","unstructured":"Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf. 2020;19:395\u2013402.","journal-title":"Expert Opin Drug Saf."},{"key":"443_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","volume":"20","author":"JE Frampton","year":"2019","unstructured":"Frampton JE. Tildrakizumab: a review in moderate-to-severe plaque psoriasis. Am J Clin Dermatol. 2019;20:295\u2013306.","journal-title":"Am J Clin Dermatol."},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","volume":"19","author":"T Torres","year":"2018","unstructured":"Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19:23\u201332.","journal-title":"Am J Clin Dermatol."},{"key":"443_CR40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","volume":"82","author":"AS Paller","year":"2020","unstructured":"Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82:389\u201397.","journal-title":"J Am Acad Dermatol."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00443-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00443-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00443-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T08:31:31Z","timestamp":1671784291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00443-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00443-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2021,4,3]]},"assertion":[{"value":"17 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MN has received honoraria for acting as a speaker from Leo Pharma. ASP is an investigator (without personal compensation) for AbbVie, AnaptysBio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis, and Sanofi-Regeneron and a consultant (with honorarium) for AbbVie, Amgen, Asana, Dermavant Sciences, Inc., Dermira, Galderma, Eli Lilly, Forte, Leo, Matrisys, Menlo, MorphoSys\/Galapagos, Novartis, Pfizer, and Sanofi-Regeneron. TT has received honoraria for acting as a consultant and\/or as a speaker from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}